Table 1.

Correlation of HDAC mRNA expression with clinical stages of GC patients.

HDACs	Clinical stages	Cases	HR (95%CI)	P value
HDAC1	1	69	0.37 (0.12–1.15)	.074
	2	145	0.72 (0.37–1.38)	.32
	3	319	0.5 (0.35–0.69)	.000032∗
	4	152	0.64 (0.43–0.94)	.023∗
HDAC2	1	69	0.35 (0.12–1.08)	.057
	2	145	1.79 (0.96–3.33)	.062
	3	319	1.25 (0.86–1.83)	.24
	4	152	0.81 (0.54–1.2)	.3
HDAC3	1	69	2.89 (1.08–7.73)	.027∗
	2	145	3.29 (1.29–8.35)	.0081∗
	3	319	1.54 (1.16–2.05)	.0029∗
	4	152	0.65 (0.43–0.99)	.044∗
HDAC4	1	69	1.95 (0.59–6.38)	.26
	2	145	1.6 (0.85–2.99)	.14
	3	319	0.69 (0.46–1.04)	.075
	4	152	1.66 (1.11–2.47)	.013∗
HDAC5	1	69	0.45 (0.13–1.57)	.2
	2	145	2.12 (1.14–3.94)	.015∗
	3	319	2.08 (1.39–3.12)	.00026∗
	4	152	1.62 (1.09–2.41)	.016∗
HDAC6	1	69	4.75 (1.72–13.08)	.00089∗
	2	145	2.08 (1.13–3.82)	.016∗
	3	319	2.29 (1.57–3.34)	.0000098∗
	4	152	1.37 (0.93–2.01)	.11
HDAC7	1	69	0.56 (0.2–1.56)	.26
	2	145	2.06 (1.12–3.77)	.018∗
	3	319	1.68 (1.26–2.23)	.00034∗
	4	152	1.58 (1.07–2.32)	.019∗
HDAC8	1	69	1.61 (0.54–4.83)	.39
	2	145	2.09 (1.12–3.92)	.018∗
	3	319	1.71 (1.16–2.51)	.006∗
	4	152	1.36 (0.91–2.03)	.14
HDAC9	1	69	0.54 (0.17–1.73)	.3
	2	145	2.06 (1.02–4.18)	.041∗
	3	319	0.79 (0.59–1.05)	.1
	4	152	1.54 (1.05–2.26)	.026∗
HDAC10	1	69	2 (0.59–6.74)	.26
	2	145	1.73 (0.84–3.54)	.13
	3	319	1.82 (1.25–2.65)	.0014∗
	4	152	1.59 (1.05–2.42)	.029∗
HDAC11	1	69	4.11 (0.53–31.66)	.14
	2	145	1.88 (0.92–3.86)	.079
	3	319	1.83 (1.23–2.71)	.0023∗
	4	152	0.73 (0.47–1.13)	.15

GC = gastric cancer; HDACs = histone deacetylases; HR = hazard ratio.

^∗P value < .05.